JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ptasznik, A.
Right arrow Articles by Bokoch, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ptasznik, A.
Right arrow Articles by Bokoch, G. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 41, Issue of October 11, 1996 pp. 25204-25207
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

A Tyrosine Kinase Signaling Pathway Accounts for the Majority of Phosphatidylinositol 3,4,5-Trisphosphate Formation in Chemoattractant-stimulated Human Neutrophils*

(Received for publication, May 25, 1996, and in revised form, July 18, 1996)

Andrzej Ptasznik Dagger §, Eric R. Prossnitz Dagger , Dan Yoshikawa , Alan Smrcka , Alexis E. Traynor-Kaplan par and Gary M. Bokoch '''''

From the Departments of Dagger  Immunology and '' Cell Biology, The Scripps Research Institute, La Jolla, California 92037, the  Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York 14642, and the par  Department of Medicine, University of California, San Diego, La Jolla, California 92037

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

The signaling pathway leading from G protein-coupled chemoattractant receptors to the generation of oxidants by NADPH oxidase in human neutrophils requires the formation of the lipid mediator phosphatidylinositol 3,4,5-trisphosphate (PIP3). Two mechanisms through which PIP3 can be generated have been described in human leukocytes. One pathway involves the coupling of the src-related tyrosine kinase Lyn to the ``classical'' p85/p110 form of phosphatidylinositol 3-kinase. The second paradigm utilizes a novel form of phosphatidylinositol 3-kinase whose activity is directly regulated by G protein beta gamma subunits. In this paper, we show that formation of PIP3 in chemoattractant-stimulated neutrophils is substantially attenuated by inhibitors that specifically block tyrosine kinase activity. These data suggest that the Lyn activation pathway plays a major role in the formation of this important lipid messenger during chemoattractant stimulation of human neutrophils.


INTRODUCTION

Phosphatidylinositol 3-kinase (PI3K)1 has been shown to be an important mediator of intracellular signaling in mammalian cells (reviewed in Refs. 1, 2, 3). The major product of PI3K, PIP3, is generated by phosphorylation of phosphatidylinositol 4,5-bisphosphate at the 3' position of the inositol ring. Formation of PIP3 has been correlated with both cytoskeletal regulation and mitogenic signaling by growth factors (1, 2, 3). In human leukocytes, studies using PI3K inhibitors indicate that PIP3 formation is a critical component of the signaling pathway leading from chemoattractant receptors to oxidant production by the NADPH oxidase (4, 5, 6, 7, 8, 9, 10). Formation of PIP3 via PI3K was originally described in chemoattractant-stimulated human neutrophils (11), and this has remained one of the best characterized cellular systems in terms of PI3K activation by G protein-coupled receptors.

Two types of PIP3-generating enzymes have been described in neutrophils. The ``classical'' form of the enzyme consists of a p110 catalytic subunit and a p85 regulatory subunit (12, 13, 14). This ubiquitous PI3K can be activated by a number of mechanisms in various cell types (1, 2, 3, 8). These mechanisms include binding of the enzyme to tyrosine-phosphorylated motifs of growth factor receptors via SH2 domains on the p85 subunit (1, 2, 15, 16, 17) and activation of the enzyme by binding of Src-family kinase SH3 domains to proline-rich domains on the p85 subunit (18). Additionally, small GTPases of the Ras and Rho families can stimulate enzyme activity (19, 20, 21, 22). Recently, a novel form of PI3K has been described in myeloid cells whose activity is directly regulated by G protein beta gamma subunits (23, 24). This form of PI3K has now been cloned and shown to consist of a unique p110gamma catalytic subunit that lacks the p85 binding domain and therefore does not associate with the p85 subunit (25).

The N-formyl peptide chemoattractant receptor couples to cell activation via heterotrimeric pertussis toxin-sensitive Gi proteins (26). As a result of Gi activation by receptor, Gbeta gamma subunits are released and can regulate a number of enzymatic activities, including the formation of IP3 and diacylglycerol via activation of PLC-beta isoforms (27, 28, 29, 30). The apparently abundant (23) Gbeta gamma -regulated PI3K would presumably be activated as well. An additional signaling pathway activated by this receptor utilizes the Lyn tyrosine kinase (7, 31). In N-formyl peptide-stimulated cells, Lyn physically and temporally associates with the classical p85/p110 form of PI3K (31). A similar situation has been observed with the B cell antigen receptor, where binding of Lyn through its SH3 domain to the p85 subunit directly activates PI3K (18). An important question that has not yet been resolved is the contribution of the Lyn-regulated PI3K pathway versus that of the Gbeta gamma -regulated enzyme to the overall formation of PIP3 in chemoattractant-stimulated neutrophils. This question is of importance for understanding the actual signaling mechanisms that couple these receptors to generation of active oxidants for the purpose of bacterial killing. In this study, we present data that indicate that a tyrosine kinase-dependent pathway presumably mediated via Lyn accounts for a majority of the PIP3 formed in response to N-formyl peptide receptor activation.


EXPERIMENTAL PROCEDURES

Lyn Kinase Assay and Shc Phosphorylation

Freshly isolated (31, 32) human neutrophils (>95% purity) were incubated in the presence or the absence of 30-200 ng/ml radicicol for 2.5 h or 100 µM genistein for 20 min at 37 °C. Cell viability was greater than 90% under these conditions (33). Lyn tyrosine kinase activity was determined after immunoprecipitation from lysates of cells stimulated for the indicated time with 1 µM fMetLeuPhe (fMLP) as described in Ref. 31. Shc phosphorylation was determined using the 4G10 anti-phosphotyrosine monoclonal antibody (Upstate Biotechnology, Inc.) as in Ref. 31.

Determination of Total Cellular PIP3

Neutrophils were suspended at a concentration of 1 × 108/ml in Buffer A (30 mM Hepes, pH 7.2, 110 mM NaCl, 10 mM KCl, 1 mM MgCl2, 10 mM glucose) and 1 mCi/ml [32P]orthophosphate (HCl-free, DuPont NEN) was added. The cells were incubated at 37 °C for 90 min and then washed three times with Buffer A. Labeled cells were treated ± 200 ng/ml radicicol for 2.5 h or 100 µM genistein for 20 min at 37 °C, and subsequently stimulated with 1 µM fMLP or buffer for the indicated times. The reaction was stopped by addition of 3 ml chloroform/methanol (1:2, v/v), followed by 4 ml chloroform/2.4 M HCl (1:1, v/v). The resulting organic lower phase was removed and the aqueous layer washed four times with 1 ml of chloroform. The combined organic phases were evaporated to dryness under N2 and resuspended in 90 µl of chloroform for thin layer chromatography (11). 20 × 20 cm Silica Gel 60 plates (EM Science) impregnated with potassium oxalate were used for analysis of lipids, with development in chloroform/acetone/methanol/acetic acid/water (80:30:26:24:14, v/v/v/v/v). Radioactive spots were detected by autoradiography using Kodak X-Omat film, and total cellular PIP3 quantified by both densitometry and an AMBIS B scanning system (San Diego, CA), with comparable results.

PI3K Activity

PIP3 formed by PI3K associated with Lyn or p85 subunit immunoprecipitates was determined as described in Refs. 4 and 31 in the presence or the absence of inhibitors. The Gbeta gamma -regulated PI3K was assayed using sonicated micelles containing 600 µM bovine liver phosphatidylethanolamine and 300 µM bovine liver phosphatidylinositol in a solution containing 40 mM NaHepes, pH 7.4/2 mM EGTA/1 mM dithiothreitol/0.2 mM EDTA/120 mM NaCl/5 mM MgCl2/1 mM beta -glycerophosphate/50 µM sodium orthovanadate/1 mg/ml bovine serum albumin. Inhibitors were added in 2 µl of dimethyl sulfoxide. Reactions were initiated by the addition of 10 µM ATP with [gamma -32P]ATP at 3.0 µCi/assay and by transfer from 4 to 30 °C. Reactions were terminated after 30 min by addition of a 2:1 methanol/chloroform solution. Samples were centrifuged, and the lower organic phase containing the lipids was extracted with a solution containing 48% methanol/3% chloroform/0.5 M HCl/1 mM EDTA/10 mM tetrabutylammonium hydrogen sulfate. The lower organic phase was dried, suspended in 2:1 methanol/chloroform, and spotted onto TLC plates that were developed with methanol/chloroform/ammonia/water (10:7:1.5:2.5) for analysis of product formation. Quantitation was by a PhosphorImager, with results presented in arbitrary units.

Partial Purification of Gbeta gamma -regulated PI3K

U937 cells were grown in 10-liter spinner flasks in RPMI 1640 with 1% fetal calf serum (UBI), 5 units/ml of penicillin, 4 µg/ml streptomycin, and 1 × lipid concentrate (Life Technologies, Inc.) at 37 °C to a density of 106 cell/ml. Cells were harvested by centrifugation at 1000 × g for 20 min, suspended in phosphate-buffered saline, pH 7.4, containing 10 mM phenylmethylsulfonyl fluoride, and collected again by centrifugation for 20 min. The cells were suspended in 75 ml of a solution of 50 mM Tris-HCl, pH 7.5/2 mM EGTA/1 mM EDTA/1 mM dithiothreitol/350 mM sucrose plus a protease inhibitor mixture (2 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml soybean trypsin inhibitor, 10 µM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin A, 10 µg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone, and 20 µg/ml 1-chloro-3-tosylamido-7-amino-2-heptanone) that was included in all of the buffers used throughout the preparation. The cells were disrupted in a Parr cell disruption bomb by rapid decompression after equilibration at 4 °C for 45 min with N2 at 500 p.s.i. Unbroken cells and intact nuclei were removed by centrifugation at 700 × g for 20 min at 4 °C. The membranes were removed by centrifugation at 100,000 × g for 1 h at 4 °C. The cytosolic supernatant was frozen in liquid N2 and stored at -70 °C until use.

A portion of the soluble fraction (10 ml at 3 mg/ml) was applied to a 1-ml Mono Q column (Pharmacia) equilibrated with Buffer B (50 mM Tris-HCl, pH 7.5/2 mM EGTA/0.2 mM EDTA/1 mM dithiothreitol/50 mM NaCl/0.05% Tween 20 and protease inhibitors). The column was washed with 60 ml of Buffer B; this was followed by elution with a gradient from 50 to 400 mM NaCl in Buffer B. Fractions were assayed in the presence and the absence of 300 µM bovine brain beta gamma (Gbeta gamma ), purified according to Sternweis and Robishaw (34). Fractions containing the highest activity in the presence of beta gamma were pooled, avoiding fractions that contained activity in the absence of beta gamma . Peak beta gamma -stimulated fractions were pooled and frozen in aliquots at -70 °C.

Measurement of Ca2+ Mobilization

Neutrophils were washed once with Hanks' balanced salt solution, resuspended to 5 × 106/ml in Hanks' balanced salt solution, and incubated with 5 µM indo-1 acetoxymethyl (1 mM stock in dimethyl sulfoxide) at 37 °C for 30 min. Cells were then washed and treated with radicicol, genistein, or buffer only exactly as described for PIP3 measurements. Following a brief wash with the same medium, neutrophils were resuspended to 15 × 106/ml in Hanks' balanced salt solution and maintained on ice until use. The cells were diluted 10-fold for assay and stimulated with 1 µM fMLP. Continuous fluorescent measurements (excitation wavelength, 340 nm) of calcium-bound and free indo-1 were made using an SLM 8000 photon counting spectrofluorimeter (SLM-Aminco) detecting at 400 and 490 nm, respectively. Intracellular free [Ca2+] during the initial phase of IP3-dependent Ca2+ entry was determined according to the equation [Ca2+]i = Kd(F - Fmin)/(Fmax - F) where Kd is 250 nM, F is the fluorescence ratio 400 nm/490 nm, Fmax is the ratio at saturating Ca2+, and Fmin is the ratio with no Ca2+ (i.e. excess EDTA).


RESULTS

Tyrosine Kinase Inhibitors Block Lyn Autophosphorylation and Shc Phosphorylation

It was previously established that human neutrophil N-formyl peptide receptors activate a signaling pathway that involves the Lyn tyrosine kinase (7, 31). Associated with Lyn immunoprecipitates in chemoattractant-stimulated neutrophils is the tyrosine-phosphorylated Shc adapter protein and the p85/p110 form of PI3K (31). The interaction of Lyn and Shc occurred through the SH2 domain of Shc and presumably required the chemoattractant-stimulated autophosphorylation of Lyn. In the present study, we observed that the tyrosine kinase inhibitor genistein at the lowest concentration exerting maximum inhibition of N-formyl peptide-stimulated oxidant production (33) almost totally blocked Lyn activity in response to fMLP (Fig. 1). Concomitantly, the tyrosine phosphorylation of Shc was also blocked by genistein (Fig. 1), consistent with the predicted need for Lyn kinase activity to mediate the interaction with and phosphorylation of Shc.


Fig. 1. Inhibition of Lyn activity, Shc phosphorylation, Lyn-associated PI3K activity, and total PIP3 by genistein in fMLP-stimulated neutrophils. Cells were treated for 20 min at 37 °C with 100 µM genistein prior to stimulation with 1 µM fMLP for 1 min, and then activities were analyzed as described under ``Experimental Procedures.'' We have previously observed that fMLP stimulation of the above activities peaks at 0.5-1 min (31). The results shown are the averages ± range of two experiments.
[View Larger Version of this Image (27K GIF file)]

Lyn-associated PIP3 Formation Is Blocked by Tyrosine Kinase Inhibitors

We determined whether the enhanced PI3K activity, which rapidly becomes associated with Lyn immunoprecipitates during leukocyte activation by chemoattractants (31), could be inhibited by tyrosine kinase inhibitors. As shown in Fig. 1, genistein effectively blocked the increases in PI3K activity observed in Lyn precipitates from stimulated neutrophils. Inhibition was constant over a 10-min time period after N-formyl peptide stimulation (data not shown). Vlahos and Matter (35) have previously established that p85/PI3K itself is not tyrosine-phosphorylated in human neutrophils, nor is it effectively inhibited directly by genistein at the concentration used in these studies (Ref. 36; data not shown). Thus, inhibition of Lyn tyrosine kinase activity is correlated with loss of Lyn-associated PIP3 formation.

The Tyrosine Kinase Inhibitor Radicicol Effectively Blocks Total PIP3 Formation in fMLP-stimulated Neutrophils

In order to address the question of the predominant source of total PIP3 formed in response to stimulation of the N-formyl peptide receptor, we examined the effect of tyrosine kinase inhibitors on total PIP3 formation. Because we detected a direct inhibitory effect of genistein on the Gbeta gamma -regulated PI3K (see Table I), we utilized a structurally and mechanistically distinct inhibitor of tyrosine kinases, radicicol, which has no effect on either Gbeta gamma -regulated PI3K (Table I) or p85 PI3K (data not shown). We confirmed that radicicol effectively inhibited activation of Lyn after fMLP-stimulation at concentrations from 30 to 200 ng/ml, with complete inhibition seen at 200 ng/ml (data not shown). This is similar to the effective doses reported in the literature for Src and Lyn kinase inhibition (37, 38, 39).

Table I.

Effects of tyrosine kinase inhibitors on PI3K activity in vitro


Assay Condition  -beta gamma +beta gamma a

Radicicol controlb 1254c 7914
+666 ng/ml radicicol 1426 7860
Genistein control 1728 8652
+100 µM genistein 1277 5514
+300 µM genistein 739 2769

a  600 µM beta gamma subunits.
b  Dimethyl sulfoxide vehicle controls were added.
c  Phosphatidylinositol 3-phosphate was quantitated on TLC plates using a PhosphorImager, which quantifies data in arbitrary units. Activity was determined as described under ``Experimental Procedures.'' Assays were performed in duplicate, and the data are representative of two separate experiments each.

Analysis of [32P]orthophosphate-labeled neutrophils showed the rapid stimulation of PIP3 formation by fMLP, with peak formation observed at 30 s to 1 min post activation, as reported previously (4, 11). Formation of PIP3 was effectively blocked at every time point by radicicol pretreatment (Fig. 2). Although fMLP increased PIP3 levels by an average of 5-fold by 30 s and 4-fold by 1 min in untreated cells, in the presence of 200 ng/ml radicicol these increases were blunted by 64.3 ± 10 and 68.3 ± 3.5% (S.D.) respectively (n = 3). Radicicol had no significant effect on unstimulated cellular levels of PIP3.


Fig. 2. PIP3 formation in fMLP-stimulated neutrophils is blocked by tyrosine kinase inhibitors. Autoradiogram of a thin layer chromatographic separation of total neutrophil phospholipids showing the time course of PIP3 formation in neutrophils treated in the presence or the absence of radicicol (200 ng/ml, 2.5 h) and subsequently stimulated with 1 µM fMLP for the indicated times. The results shown are representative of three similar experiments; analogous results were obtained with 100 µM genistein. PC, phosphatidylcholine; PI, phosphatidylinositol; PIP, phosphatidylinositol 4-phosphate; PIP2, phosphatidylinositol 4,5 bisphosphate.
[View Larger Version of this Image (49K GIF file)]

Tyrosine Kinase Inhibitors Do Not Block All Gbeta gamma -mediated Signaling Pathways

In order to make certain that the tyrosine kinase inhibitors genistein and radicicol did not exert nonspecific effects on Gbeta gamma -mediated signaling that could account for some of the block of PIP3 formation, we measured fMLP-stimulated Ca2+ mobilization. It has been established that increases in intracellular Ca2+ by N-formyl peptides results from the mobilization of intracellular Ca2 stores by inositol trisphosphate generated as a result of phospholipase C activation (8, 40, 41, 42). In human neutrophils, this occurs solely through Gbeta gamma -regulated PLC beta  isoforms (27, 28, 29). As shown in Fig. 3, neither genistein nor radicicol significantly prevented the increases in intracellular Ca2+ induced by fMLP. Thus, these drugs did not exert any direct inhibitory effect on Gbeta gamma function.


Fig. 3. Genistein and radicicol do not block Gbeta gamma -dependent Ca2+ mobilization. The mobilization of intracellular Ca2+ by 1 µM fMLP, a phospholipase C-dependent process, was determined as described under ``Experimental Procedures'' in the absence (Con) or presence of 100 µM genistein (Gen) or 200 ng/ml radicicol (Rad). The results shown represent the averages ± range of two separate determinations with different cell donors.
[View Larger Version of this Image (17K GIF file)]

Genistein but Not Radicicol Inhibits the Gbeta gamma -regulated PI3K

In our initial studies, we had used genistein as a ``specific'' tyrosine kinase inhibitor (43) and observed that it caused a dramatic inhibition of PIP3 formation in response to fMLP (i.e. greater than 90%, see Fig. 1). When we performed control experiments to examine whether genistein had any direct effect on the beta gamma -regulated PI3K, we found that genistein attenuated the catalytic activity of the isolated enzyme. As shown in Table I, genistein caused inhibition of both the basal and beta gamma -stimulated activity of the partially purified U937 cell beta gamma -sensitive PI3K. At the concentrations used in Fig. 1, 100 µM, inhibition was only partial (~30-40%). Inhibition approached 100% at higher concentrations of the drug. In contrast to genistein, radicicol had no inhibitory effect even at high concentrations, up to 666 ng/ml. Similar results were obtained using a recombinant p110gamma catalytic subunit.


DISCUSSION

We previously demonstrated that the Shc adapter protein was phosphorylated on tyrosine in response to chemoattractant receptor activation and that this phosphorylated Shc was physically associated with Lyn (31). In the present study, we provide further evidence that Shc is tyrosine-phosphorylated by Lyn by demonstrating that blockade of Lyn tyrosine kinase activity inhibits Shc phosphorylation (Fig. 1). This is consistent with our results showing that the interaction of Lyn and Shc occurs via a Shc SH2 domain (31).

The data presented here strongly indicate that the Lyn-regulated PI3K pathway of PIP3 formation is of primary importance quantitatively during chemoattractant-mediated leukocyte activation. We have previously shown that the enhancement of PI3K activity associated with Lyn immunoprecipitates is rapid and parallels both PIP3 formation and cell activation (4, 31). This is in contrast to the data of Stephens et al. (7), who reported Lyn-associated PIP3 formation was much slower. The Src tyrosine kinase inhibitor radicicol substantially attenuated the rise in PIP3 formation stimulated by the chemoattractant fMetLeuPhe at a concentration that totally blocked stimulated Lyn tyrosine kinase activity (Fig. 2). This inhibition was not due to a direct inhibitory effect on either the p85/p110 PI3K or the beta gamma -regulated enzyme (Table I), nor was there any nonspecific inhibition of beta gamma -mediated signaling in general (Fig. 3). Because there is no involvement of nor requirement for a tyrosine kinase in activating the beta gamma -regulated enzyme (23, 24, 25), our data strongly point to the Lyn pathway as a quantitatively important source of PIP3 during early neutrophil activation. Radicicol inhibited the increase in cellular PIP3 levels by nearly 70%, indicating that at least two-thirds of the PIP3 formed originated from a tyrosine kinase-regulated PI3K pathway rather than from the beta gamma -regulated enzyme. Indeed, if the decrease in actual mass of PIP3 product formed is considered, the level of inhibition is even greater. An alternative explanation for our results would have to invoke the need for a tyrosine kinase for in vivo activation of the beta gamma -regulated PI3K, a hypothesis for which there is no supporting evidence.

The predominant importance of the tyrosine kinase-requiring PI3K pathway is also evidenced by the data we obtained with genistein. Although not as clearcut as the radicicol data, we observed that genistein almost completely blocked (>90%) chemoattractant-stimulated PIP3 formation while not decreasing unstimulated levels of PIP3. Even taking into account the inhibition that could occur due to direct effects on PI3K itself (30-40% in vitro), the majority of the inhibition appears to be as a result of tyrosine kinase blockade. The observation that genistein was a direct inhibitor of the beta gamma -sensitive PI3K (p110gamma ) at higher concentrations may have bearing on the widespread use of this compound as a specific inhibitor of tyrosine kinases (43). It is clear that at higher concentrations genistein can interact with the p110gamma and the p85-associated p110 isoforms (alpha , beta ) as well (36). This is likely to be due to the ability of genistein to compete with ATP for binding to the enzyme (43). Because radicicol is structurally distinct from genistein and inhibits tyrosine kinases in a manner noncompetitive with ATP (37, 38), it has no effect on either form of PI3K.

In summary, we have provided evidence that a tyrosine kinase-requiring pathway likely to be the Lyn pathway is quantitatively predominant for formation of the lipid mediator PIP3 during early leukocyte activation by chemoattractants. Thus, the regulation of neutrophil functions that depend upon PIP3 formation, such as oxidant formation via the NADPH oxidase (9, 10), is likely to occur via the tyrosine kinase-initiated pathway. The Rac GTPase is a critical regulator of the NADPH oxidase (44), and we have previously shown that Rac translocation from cytosolic complex to membrane oxidase requires the activity of a tyrosine kinase (33). PI3K activity has also been implicated in Rac activation (45). The data presented here reconcile these observations by demonstrating the primary importance of the tyrosine kinase mechanism for generating the lipid mediator PIP3 in chemoattractant-stimulated human neutrophils.


FOOTNOTES

*   This work was supported by National Institutes of Health Grants GM44428 and GM39434 (to G. M. B.), DK47240 (to A. T. K.), and AI36357 (to E. R. P.) and a PhRMA Foundation Research Starter grant (to A. S.), as well as a Miles and Shirley Fitterman Research Award (to A. T. K.). This is publication 10100-IMM from The Scripps Research Institute. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: University of California, San Diego, The Whittier Inst., 9894 Genesee Ave., La Jolla, CA 92037. Tel.: 619-622-8441; Fax: 619-558-3495.
'''   To whom correspondence should be addressed: Dept. of Immunology-IMM14, The Scripps Research Inst., 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 619-554-8217; Fax: 619-554-8218.
1   The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; fMLP, formylmethionylleucylphenylalanine.

Acknowledgments

We thank Eleanora Wolfson for expert technical assistance. Antonette Lestelle is gratefully acknowledged for help in manuscript preparation.


REFERENCES

  1. Divecha, N., Irvine, R. F. (1995) Cell 80, 269-278 [CrossRef][Medline] [Order article via Infotrieve]
  2. Kazlauskas, A. (1994) Curr. Opin. Genet. & Dev. 4, 5-14 [CrossRef][Medline] [Order article via Infotrieve]
  3. Downes, C. P., Carter, A. N. (1991) Cell. Signal. 3, 501-513 [CrossRef][Medline] [Order article via Infotrieve]
  4. Traynor-Kaplan, A. E., Thompson, B. L., Harris, A. L., Taylor, P., Omann, G. M., Sklar, L. A. (1989) J. Biol. Chem. 264, 15668-15673 [Abstract/Free Full Text]
  5. Stephens, L. R., Hughes, K. T., Irvine, R. F. (1991) Nature 351, 33-39 [CrossRef][Medline] [Order article via Infotrieve]
  6. Stephens, L., Jackson, T., Hawkins, P. T. (1993) J. Biol. Chem. 268, 17162-17172 [Abstract/Free Full Text]
  7. Stephens, L., Equinoa, A., Corey, S., Jackson, T., Hawkins, T. (1993) EMBO J. 12, 2265-2273 [Medline] [Order article via Infotrieve]
  8. Thelen, M., Wirthmueller, U. (1994) Curr. Opin. Immunol. 6, 106-112 [CrossRef][Medline] [Order article via Infotrieve]
  9. Arcaro, A., Wymann, M. P. (1993) Biochem. J. 296, 297-301
  10. Vlahos, C. J., Matter, W. F., Brown, R. F., Traynor-Kaplan, A. E., Heyworth, P. G., Prossnitz, E. R., Ye, R. D., Marder, P., Schelm, J. A., Rothfuss, K. J., Serlin, B. S., Simpson, P. J. (1995) J. Immunol. 154, 2413-2422 [Abstract]
  11. Traynor-Kaplan, A. E., Harris, A. L., Thompson, B. L., Taylor, P., Sklar, L. A. (1988) Nature 334, 353-356 [CrossRef][Medline] [Order article via Infotrieve]
  12. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfray, D., Fried, V. A., Williams, L. T. (1991) Cell 65, 75-82 [CrossRef][Medline] [Order article via Infotrieve]
  13. Skolnik, E. Y., Margolis, B., Mohamnudi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., Schlessinger, J. (1991) Cell 65, 83-90 [CrossRef][Medline] [Order article via Infotrieve]
  14. Otsu, M., Hiles, I., Gout, I., Fry, M. J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhanal, R., Hsuan, J., Totty, N., Smith, A. D., Morgan, S. J., Courtneidge, S. A., Parker, P. J., Waterfield, M. D. (1992) Cell 65, 91-104
  15. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhaml, R., Panayotou, G., Ruiz-Larvea, F., Thompson, A., Totty, N. F., Hsuan, J. J., Courtneidge, S. A., Parker, P. J., Waterfield, M. D. (1992) Cell 70, 419-429 [CrossRef][Medline] [Order article via Infotrieve]
  16. Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., Cantley, L. C. (1993) J. Biol. Chem. 268, 9478-9483 [Abstract/Free Full Text]
  17. Rordorf-Nikolic, T., Van Horn, D. J., Chen, D., White, M. F., Backer, J. M. (1995) J. Biol. Chem. 270, 3662-3666 [Abstract/Free Full Text]
  18. Pleiman, C. M., Hertz, W. M., Cambier, J. C. (1994) Science 263, 1609-1612 [Abstract/Free Full Text]
  19. Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  20. Zheng, Y., Bagrodia, S., Cerione, R. A. (1994) J. Biol. Chem. 269, 18727-18730 [Abstract/Free Full Text]
  21. Tolias, K. F., Cantley, L. C., Carpenter, C. L. (1995) J. Biol. Chem. 270, 17656-17659 [Abstract/Free Full Text]
  22. Bokoch, G. M., Vlahos, C. J., Wang, Y., Knaus, U. G., Traynor-Kaplan, A. E. (1996) Biochem. J. 315, 775-779
  23. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., Hawkins, P. T. (1994) Cell 77, 83-93 [CrossRef][Medline] [Order article via Infotrieve]
  24. Thomason, P. A., Janes, S. R., Casey, P. J., Downes, C. P. (1994) J. Biol. Chem. 269, 16525-16528 [Abstract/Free Full Text]
  25. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nürnberg, B., Gierschik, P., Seedorf, K., Hsuan, J. J., Waterfield, M. D., Wetzker, R. (1995) Science 269, 690-693 [Abstract/Free Full Text]
  26. Bokoch, G. M. (1991) Current Topics in Membranes and Transport (Grinstein, S., Rotstein, O. D., eds) , p. 65, Academic Press, Orlando, FL
  27. Camps, M., Hou, C., Sidiropoulos, D., Stock, J. B., Jakobs, K. H., Gierschik, P. (1992) Eur. J. Biochem. 206, 821-831 [Medline] [Order article via Infotrieve]
  28. Camps, M., Carozzi, A., Schnabel, P., Scheer, A., Parker, P. J., Gierschik, P. (1992) Nature 360, 684-686 [CrossRef][Medline] [Order article via Infotrieve]
  29. Katz, A., Wu, D., Simon, H. I. (1992) Nature 360, 686-689 [CrossRef][Medline] [Order article via Infotrieve]
  30. Smrcka, A. V., Sternweis, P. C. (1993) J. Biol. Chem. 268, 9667-9674 [Abstract/Free Full Text]
  31. Ptasznik, A., Traynor-Kaplan, A., Bokoch, G. M. (1995) J. Biol. Chem. 270, 19969-19973 [Abstract/Free Full Text]
  32. Dobos, G. J., Norgauer, J., Eberle, M., Schollmeyer, P. J., Traynor-Kaplan, A. (1992) J. Immunol. 149, 609-614 [Abstract]
  33. Dorseuil, O., Quinn, M. T., Bokoch, G. M. (1995) J. Leukocyte Biol. 58, 108-113 [Abstract]
  34. Sternweis, P. C., Robishaw, J. D. (1984) J. Biol. Chem. 259, 13806-13813 [Abstract/Free Full Text]
  35. Vlahos, C. J., Matter, W. F. (1992) FEBS Lett. 309, 242-248 [CrossRef][Medline] [Order article via Infotrieve]
  36. Matter, W. F., Brown, R. F., Vlahos, C. J. (1992) Biochem. Biophys. Res. Commun. 186, 624-631 [CrossRef][Medline] [Order article via Infotrieve]
  37. Kwon, J. J., Yoshida, M., Abe, K., Horinouchi, S., Beppu, T. (1992) Biosci. Biotechnol. Biochem. 56, 538-539 [Medline] [Order article via Infotrieve]
  38. Kwon, H. J., Yoshida, M., Fukui, Y., Horinouchi, S., Beppu, T. (1992) Cancer Res. 52, 6926-6930 [Abstract/Free Full Text]
  39. Chanmugam, P., Feng, L., Liou, S., Jang, B. C., Boudreau, M., Yu, G., Lee, J. H., Kwon, H. J., Beppu, T., Yoshida, M., Xia, Y., Wilson, C. B., Hwang, D. (1995) J. Biol. Chem. 270, 5418-5426 [Abstract/Free Full Text]
  40. Cockroft, S. (1992) Biochim. Biophys. Acta. 1113, 135-160 [Medline] [Order article via Infotrieve]
  41. Thelen, M., Dewald, B., Baggiolini, M. (1993) Physiol. Rev. 73, 797-821 [Free Full Text]
  42. Lew, D. P., Krause, K. (1993) Curr. Opin. Hematol. 1993, 106-112
  43. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., Fukami, Y. (1987) J. Biol. Chem. 262, 5592-5595 [Abstract/Free Full Text]
  44. Bokoch, G. M. (1994) Curr. Opin. Cell Biol. 6, 212-218 [CrossRef][Medline] [Order article via Infotrieve]
  45. Wennström, S., Hawkins, P., Cooke, F., Hara, K., Yonezawa, K., Kasuga, M., Jackson, T., Claesson-Welsh, L., Stephens, L. (1994) Curr. Biol. 4, 385-393 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
Z. Hu, I. H. Lee, X. Wang, H. Sheng, L. Zhang, J. Du, and W. E. Mitch
PTEN Expression Contributes to the Regulation of Muscle Protein Degradation in Diabetes
Diabetes, October 1, 2007; 56(10): 2449 - 2456.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. B. Lee, I. H. Bae, Y. S. Bae, and H.-D. Um
Link between Mitochondria and NADPH Oxidase 1 Isozyme for the Sustained Production of Reactive Oxygen Species and Cell Death
J. Biol. Chem., November 24, 2006; 281(47): 36228 - 36235.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Boulven, S. Levasseur, S. Marois, G. Pare, E. Rollet-Labelle, and P. H. Naccache
Class IA Phosphatidylinositide 3-Kinases, rather than p110{gamma}, Regulate Formyl-Methionyl-Leucyl-Phenylalanine-Stimulated Chemotaxis and Superoxide Production in Differentiated Neutrophil-Like PLB-985 Cells.
J. Immunol., June 15, 2006; 176(12): 7621 - 7627.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Nakata, B. Tomkowicz, A. M. Gewirtz, and A. Ptasznik
Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells
Blood, June 1, 2006; 107(11): 4234 - 4239.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. M. Condliffe, K. Davidson, K. E. Anderson, C. D. Ellson, T. Crabbe, K. Okkenhaug, B. Vanhaesebroeck, M. Turner, L. Webb, M. P. Wymann, et al.
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils
Blood, August 15, 2005; 106(4): 1432 - 1440.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. M. Williams and C. O. S. Savage
Characterization of the Regulation and Functional Consequences of p21ras Activation in Neutrophils by Antineutrophil Cytoplasm Antibodies
J. Am. Soc. Nephrol., January 1, 2005; 16(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. M. Fuhler, K. A. Cadwallader, G. J. Knol, E. R. Chilvers, A. L. Drayer, and E. Vellenga
Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia
J. Leukoc. Biol., July 1, 2004; 76(1): 254 - 262.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. D. Puri, T. A. Doggett, J. Douangpanya, Y. Hou, W. T. Tino, T. Wilson, T. Graf, E. Clayton, M. Turner, J. S. Hayflick, et al.
Mechanisms and implications of phosphoinositide 3-kinase {delta} in promoting neutrophil trafficking into inflamed tissue
Blood, May 1, 2004; 103(9): 3448 - 3456.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Kim, C. C. Marchal, J. Penninger, and M. C. Dinauer
The Hemopoietic Rho/Rac Guanine Nucleotide Exchange Factor Vav1 Regulates N-Formyl-Methionyl-Leucyl-Phenylalanine-Activated Neutrophil Functions
J. Immunol., October 15, 2003; 171(8): 4425 - 4430.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Misra, L. Varticovski, and I. M. Arias
Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles
Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G316 - G324.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Sadhu, B. Masinovsky, K. Dick, C. G. Sowell, and D. E. Staunton
Essential Role of Phosphoinositide 3-Kinase {delta} in Neutrophil Directional Movement
J. Immunol., March 1, 2003; 170(5): 2647 - 2654.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. Y. Channon, K. A. Miselis, L. A. Minns, C. Dutta, and L. H. Kasper
Toxoplasma gondii Induces Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Secretion by Human Fibroblasts: Implications for Neutrophil Apoptosis
Infect. Immun., November 1, 2002; 70(11): 6048 - 6057.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Li, A. Yamauchi, C. C. Marchal, J. K. Molitoris, L. A. Quilliam, and M. C. Dinauer
Chemoattractant-Stimulated Rac Activation in Wild-Type and Rac2-Deficient Murine Neutrophils: Preferential Activation of Rac2 and Rac2 Gene Dosage Effect on Neutrophil Functions
J. Immunol., November 1, 2002; 169(9): 5043 - 5051.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
N. Fazal, W. M. Al-Ghoul, M. J. Schmidt, M. A. Choudhry, and M. M. Sayeed
Lyn- and ERK-mediated vs. Ca2+-mediated neutrophil O2- responses with thermal injury
Am J Physiol Cell Physiol, November 1, 2002; 283(5): C1469 - C1479.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. A. Cadwallader, A. M. Condliffe, A. McGregor, T. R. Walker, J. F. White, L. R. Stephens, and E. R. Chilvers
Regulation of Phosphatidylinositol 3-Kinase Activity and Phosphatidylinositol 3,4,5-Trisphosphate Accumulation by Neutrophil Priming Agents
J. Immunol., September 15, 2002; 169(6): 3336 - 3344.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
A. Ptasznik, E. Urbanowska, S. Chinta, M. A. Costa, B. A. Katz, M. A. Stanislaus, G. Demir, D. Linnekin, Z. K. Pan, and A. M. Gewirtz
Crosstalk Between BCR/ABL Oncoprotein and CXCR4 Signaling through a Src Family Kinase in Human Leukemia Cells
J. Exp. Med., September 2, 2002; 196(5): 667 - 678.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. Nijhuis, J.-W. J Lammers, L. Koenderman, and P. J. Coffer
Src kinases regulate PKB activation and modulate cytokine and chemoattractant-controlled neutrophil functioning
J. Leukoc. Biol., January 1, 2002; 71(1): 115 - 124.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Ben-Smith, S. K. Dove, A. Martin, M. J. O. Wakelam, and C. O. S. Savage
Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fc{gamma} receptor ligation
Blood, September 1, 2001; 98(5): 1448 - 1455.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. S. Manetz, C. Gonzalez-Espinosa, R. Arudchandran, S. Xirasagar, V. Tybulewicz, and J. Rivera
Vav1 Regulates Phospholipase C{gamma} Activation and Calcium Responses in Mast Cells
Mol. Cell. Biol., June 1, 2001; 21(11): 3763 - 3774.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
J. Kruger, J. R. Butler, V. Cherapanov, Q. Dong, H. Ginzberg, A. Govindarajan, S. Grinstein, K. A. Siminovitch, and G. P. Downey
Deficiency of Src Homology 2-Containing Phosphatase 1 Results in Abnormalities in Murine Neutrophil Function: Studies in Motheaten Mice
J. Immunol., November 15, 2000; 165(10): 5847 - 5859.
[Abstract] [Full Text] [PDF]